Anemia Significantly Correlated With COVID-19 Mortality

Article

Anemia is both common and independently associated with poor clinical outcomes in respiratory infections, including COVID-19.

Anemia is both common and independently associated with poor clinical outcomes in respiratory infections, including COVID-19.

Image courtesy of Adobe Stock/ vchalup

Despite all the advances in COVID-19 vaccines and treatments, some patients still experience severe or fatal disease progression. Thus, there remains an impetus to identify any and all factors that may increase the risk of COVID-19 morbidity and mortality.

One study, presented this week at the 2023 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), noted that evidence about the prevalence and prognosis of anemia in hospitalized COVID-19 patients is still ambiguous.

The investigators examined the association between COVID-19 patients’ anemia at hospital admission and incidence of severe disease and death.

The study authors referenced background information that anemia is known to be both a consequence of acute inflammation and a predictor of poor clinical outcomes in respiratory infections. In COVID-19 patients, the overexpression of overexpression of interleukin (IL)-1, IL-6, interferon-γ, and tumor necrosis factor (TNF)-α profoundly affect iron metabolism and erythropoiesis, which causes anemia.

This retrospective study was conducted in 2 teaching hospital in southern Italy. From September 1, 2020-August 31, 2022, the investigators collected data from all adult patients admitted for COVID-19. They determined the association between anemia, severe COVID-19, and in-hospital mortality using a Cox’s regression analysis.

“Anemia” was defined as a reduction in hemoglobin (Hb) <13 g/dl in men and <12 g/dl in women. “Severe COVID-19” was defined as admission to intensive or subintensive care unit, or a quick SOFA (qSOFA) score ≥2 or CURB-65 score ≥3. Using a propensity score, the association between anemia and mortality was adjusted in 2 models for the potential cofounders.

A total of 1562 patients were included in the analyses. Of the hospitalized COVID-19 patients, anemia prevalence was determined to be 45.1%. The patients were also significantly older, reported more comorbidities, and presented with higher levels of procalcitonin, CRP, ferritin, and IL-6.

The patients with anemia had a crude mortality incidence about 4 times higher than the hospitalized COVID-19 patients without anemia. After adjusting the results for 17 potential confounders, the investigators determined anemia significantly increased the risk of severe COVID-19 and death. These results were confirmed by the propensity score analysis.

The investigators concluded that anemia is associated with a more pronounced baseline proinflammatory profile in hospitalized COVID-19 patients, as well as a higher incidence of severe disease and in-hospital mortality.

This study, “Anemia as a predictor of poor clinical outcome in patients admitted for COVID-19: a large, multi-centre, retrospective cohort study,” was presented during a poster session at ECCMID 2023.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.